 |
12/22/2005
PTC THERAPEUTICS INITIATES SECOND PHASE 2 STUDY OF PTC124 IN PATIENTS WITH CYSTIC FIBROSIS IN ISRAEL
|
46.7 KB |
| |
SOUTH PLAINFIELD, NJ - December 22, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced the initiation of a Phase 2 study of PTC124 at Hadassah University Hospital in Israel in patients...
|
|
12/19/2005
PARENT PROJECT MUSCULAR DYSTROPHY ANNOUNCES SUCCESSFUL COMPLETION OF STAGE 1 OF DRUG DISCOVERY COLLABORATION WITH PTC THERAPEUTICS, INC.
|
49.1 KB |
| |
(MIDDLETOWN, Ohio) - December 19, 2005 - Parent Project Muscular Dystrophy (PPMD) announced today that Stage 1 (Discovery) of its collaboration with PTC Therapeutics, Inc. (PTC), of South Plainfield, NJ, has been completed successfully. PPMD and PTC are collaborating to discover new drugs to treat Duchenne muscular dystrophy (DMD). The Discovery st...
|
|
12/19/2005
PTC THERAPEUTICS NAMES DAVID P. SOUTHWELL TO ITS BOARD OF DIRECTORS
|
46.4 KB |
| |
SOUTH PLAINFIELD, NJ - December 19, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today named David P. Southwell to its Board of Directors."Mr. Southwell brings additional broad-based...
|
|
12/06/2005
FDA'S OFFICE OF ORPHAN PRODUCTS DEVELOPMENT AWARDS PTC THERAPEUTICS A GRANT TO SUPPORT CLINICAL DEVELOPMENT OF PTC124 FOR THE TREATMENT OF NONSENSE-MUTATION-MEDIATED CYSTIC FIBROSIS
|
49.8 KB |
| |
SOUTH PLAINFIELD, NJ - December 6, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced the company has been awarded a two-year grant from the Office of Orphan Products Development (OOPD...
|
|
12/06/2005
PTC THERAPEUTICS INITIATES PHASE 2 STUDY OF PTC124 IN CYSTIC FIBROSIS
|
45.3 KB |
| |
SOUTH PLAINFIELD, NJ - December 6, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced the initiation of a Phase 2 study of PTC124 in patients with cystic fibrosis (CF) due to a nonsens...
|
|
12/01/2005
BAUSCH & LOMB AND PTC THERAPEUTICS ANNOUNCE
ANTI-ANGIOGENESIS COLLABORATION IN OPHTHALMOLOGY
|
52.1 KB |
| |
ROCHESTER, N.Y. and SOUTH PLAINFIELD, N.J. - Bausch & Lomb (NYSE:BOL) and PTC Therapeutics, Inc., a privately held biopharmaceutical company, today announced an exclusive option agreement for Bausch & Lomb to license selected PTC compounds as development candidates for therapeutic use in ophthalmology.
PTC's anti-angiogenesis program was de...
|
|
11/10/2005
PTC THERAPEUTICS RAISES $26.6 MILLION IN PRIVATE PLACEMENT FINANCING
|
45.8 KB |
| |
SOUTH PLAINFIELD, NJ - November 10, 2005 - PTC Therapeutics, Inc. (PTC), a privately held biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced the closing of a $26.6 million equity financing. The round was led by current inv...
|
|
07/07/2005
EUROPEAN MEDICINES AGENCY (EMEA) GRANTS PTC THERAPEUTICS ORPHAN DRUG DESIGNATION FOR PTC124 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY AND CYSTIC FIBROSIS
|
51.9 KB |
| |
SOUTH PLAINFIELD, NJ - July 7, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that PTC124 has been granted orphan drug status for the treatment of Duchenne muscular dystrophy (DMD)...
|
|
06/29/2005
PTC THERAPEUTICS PRESENTS DATA FROM PHASE 1 STUDIES AND DESIGN OF PHASE 2 STUDIES FOR PTC124 AT THE 28TH EUROPEAN CYSTIC FIBROSIS CONFERENCE
|
50.3 KB |
| |
SOUTH PLAINFIELD, NJ - June 29, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that complete data from the Phase 1 single- and multiple-dose studies and design of the planned Phase...
|
|
05/18/2005
PTC THERAPEUTICS ANNOUNCES PROMOTION OF
WILLIAM BAIRD TO CHIEF FINANCIAL OFFICER
|
45.8 KB |
| |
SOUTH PLAINFIELD, NJ - May 18, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced the promotion of William "Chip" Baird to the newly-created position of Chief Financial Officer. Mr. B...
|
|
04/21/2005
PTC THERAPEUTICS RECEIVES $1.5 MILLION GRANT FROM MUSCULAR DYSTROPHY ASSOCIATION
|
48.9 KB |
| |
SOUTH PLAINFIELD, NJ - April 21, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that the company has been awarded a $1.5 million grant from the Muscular Dystrophy Association (MDA)...
|
|
04/11/2005
PTC THERAPEUTICS PRESENTS DATA FROM PHASE 1 MULTIPLE-DOSE STUDY OF PTC124 AT THE 2005 AMERICAN ACADEMY OF NEUROLOGY MEETING
|
66.7 KB |
| |
SOUTH PLAINFIELD, NJ - April 11, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that data from the Phase 1 multiple- dose study of PTC124 were presented at the 57th Annual meeting ...
|
|
03/31/2005
PTC THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FOR PTC124
|
64.7 KB |
| |
SOUTH PLAINFIELD, NJ - March 31, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that the company has been granted fast track designation from the United States Food and Drug Admini...
|
|
02/21/2005
PTC THERAPEUTICS RECEIVES $1.7 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF PTC124
|
48.0 KB |
| |
SOUTH PLAINFIELD, NJ - February 21, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that the company has been awarded $1.7 million from Cystic Fibrosis Foundation Therapeutics, Inc....
|
|
01/27/2005
PTC THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR PTC124 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
|
66.4 KB |
| |
SOUTH PLAINFIELD, NJ - January 27, 2005 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to P...
|
| Showing 1-15 of 15 |
Page: 1 |
|
|